MOUNTAIN VIEW, Calif., Aug. 24, 2011 (GLOBE NEWSWIRE) -- Complete Genomics Inc. (Nasdaq:GNOM), the complete human genome sequencing company, today announced additional details about the option that SAIC-Frederick Inc. has exercised to have Complete Genomics sequence the DNA from more than 500 pediatric cancer cases. This project was first announced during Complete Genomics' Q2 earnings call on Aug. 4, 2011. Each case consists of a tumor-normal pair, and some cases include a relapsed tumor. This additional study follows the first phase of the project in which Complete Genomics sequenced and analyzed 100 genomes (50 tumor-normal pairs) from pediatric cancer cases on behalf of SAIC-Frederick Inc., which is the prime contractor for the NCI's R&D facility in Frederick, Md., under contract HHSN261200800001E.
